Massar Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Massar Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$897K	Sell	50,278 -156,692	-76%	-$1.96M	0.09%	106
2026 Q1	$1.88M	Buy	206,970 +30,742	+17%	+$388K	0.2%	78
2025 Q4	$2.41M	Buy	176,228 +112,228	+175%	+$2.08M	0.26%	65
2025 Q3	$1.39M	Sell	64,000 -6,000	-9%	-$70.7K	0.18%	78
2025 Q2	$836K	Hold	70,000	–	–	0.62%	48
2025 Q1	$832K	Buy	+70,000	New	+$1.09M	0.93%	23

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Massar Capital Management's CLPT Position: Q2 2026 in Review

Massar Capital Management reduced its ClearPoint Neuro (CLPT) stake by 76% in Q2 2026, selling an estimated $1.96M and leaving 50,278 shares worth $897K. The position accounts for 0.09% of the portfolio, ranked #106.

Massar Capital Management first reported a position in CLPT in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.41M in Q4 2025. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Massar Capital Management held 50,278 shares of ClearPoint Neuro worth $897K as of Q2 2026.
Massar Capital Management sold 156,692 ClearPoint Neuro shares in Q2 2026, an estimated $1.96M.
ClearPoint Neuro made up 0.09% of Massar Capital Management's portfolio in Q2 2026, its #106 holding.
Massar Capital Management first reported a position in ClearPoint Neuro in Q1 2025 and has held it in 6 quarters since.
Massar Capital Management's ClearPoint Neuro position peaked at $2.41M in Q4 2025.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Massar Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.